Takeda's mid-term recipe: emerging markets, efficiency, R&D
This article was originally published in Scrip
Executive Summary
Takeda sees light at the end of the tunnel, but while it's no longer an oncoming patent cliff train, for the immediate future "it's not as bright as we had expected," president and CEO Yasuchika Hasegawa declared at the leading Japanese pharma company's results briefing in Tokyo.